Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis

References

• Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9
   PubMed Web of Science ®Google Scholar
• Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602
   PubMed Web of Science ®Google Scholar
• Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003; 62: 245–7
   PubMed Web of Science ®Google Scholar
• Gerloni V., Pontikaki I., Gattinara M., Desiati F., Lupi E., Lurati A., et al. Efficacy of repeated intravenous infusions of an anti‐tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open‐label prospective study. Arthritis Rheum 2005; 52: 548–53
   PubMed Web of Science ®Google Scholar
• Feldmann M., Maini R. N. Anti‐TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001; 19: 163–96
   PubMed Web of Science ®Google Scholar
• Giannini E. H., Ruperto N., Ravelli A., Lovell D. J., Felson D. T., Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–9
   PubMed Web of Science ®Google Scholar
• Campbell I. K., Roberts L. J., Wicks I. P. Molecular targets in immune‐mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol 2003; 81: 354–66
   PubMed Web of Science ®Google Scholar
• Modesto C., Patino‐Garcia A., Sotillo‐Pineiro E., Merino J., Garcia‐Consuegra J., Merino R., et al. TNF‐alpha promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemic‐onset juvenile idiopathic arthritis. Scand J Rheumatol 2005; 34: 451–4
   PubMed Web of Science ®Google Scholar
• Mangge H., Kenzian H., Gallistl S., Neuwirth G., Liebmann P., Kaulfersch W., et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 38: 211–20
   PubMed Web of Science ®Google Scholar
• Wong P. K., Campbell I. K., Egan P. J., Ernst M., Wicks I. P. The role of the interleukin‐6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003; 48: 1177–89
   PubMed Web of Science ®Google Scholar
• Charles P., Elliott M. J., Davis D., Potter A., Kalden J. R., Antoni C., et al. Regulation of cytokines, cytokine inhibitors, and acute‐phase proteins following anti‐TNF‐alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521–8
   PubMed Web of Science ®Google Scholar
• Marotte H., Maslinski W., Miossec P. Circulating tumour necrosis factor‐alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 2005; 7: R149–55
   PubMed Web of Science ®Google Scholar
• Torsteinsdottir I., Hakansson L., Hallgren R., Gudbjornsson B., Arvidson N. G., Venge P. Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 1249–54
   PubMed Web of Science ®Google Scholar
• Lefkowitz D. L., Lefkowitz S. S. Macrophage–neutrophil interaction: a paradigm for chronic inflammation revisited. Immunol Cell Biol 2001; 79: 502–6
   PubMed Web of Science ®Google Scholar
• Tak P. P., Taylor P. C., Breedveld F. C., Smeets T. J., Daha M. R., Kluin P. M., et al. Decrease in cellularity and expression of adhesion molecules by anti‐tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077–81
   PubMed Web of Science ®Google Scholar
• Foell D., Wittkowski H., Hammerschmidt I., Wulffraat N., Schmeling H., Frosch M., et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serumconcentrations. Arthritis Rheum 2004; 50: 1286–95
   PubMed Web of Science ®Google Scholar
• Kopp S., Alstergren P., Ernestam S., Nordahl S., Morin P., Bratt J. Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis. Cells Tissues Organs 2005; 180: 22–30
   PubMed Web of Science ®Google Scholar
• Mojcik C. F., Shevach E. M. Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 1997; 40: 991–1004
   PubMed Web of Science ®Google Scholar
• De Benedetti F., Vivarelli M., Pignatti P., Oliveri M., Massa M., Pistorio A., et al. Circulating levels of soluble E‐selectin, P‐selectin and intercellular adhesion molecule‐1 in patients with juvenile idiopathic arthritis. J Rheumatol 2000; 27: 2246–50
   PubMedGoogle Scholar
• Chen C. Y., Tsao C. H., Ou L. S., Yang M. H., Kuo M. L., Huang J. L. Comparison of soluble adhesion molecules in juvenile idiopathic arthritis between the active and remission stages. Ann Rheum Dis 2002; 61: 167–70
   PubMedGoogle Scholar
• Bloom B. J., Nelson S. M., Eisenberg D., Alario A. J. Soluble intercellular adhesion molecule‐1 and E‐selectin as markers of disease activity and endothelial activation in juvenile idiopathic arthritis. J Rheumatol 2005; 32: 366–72
   PubMed Web of Science ®Google Scholar
• Klimiuk P. A., Sierakowski S., Domyslawska I., Fiedorczyk M., Chwiecko J. Reduction of soluble adhesion molecules (sICAM‐1, sVCAM‐1, and sE‐selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp 2004; 52: 36–42
   PubMed Web of Science ®Google Scholar
• Adarichev V. A., Vermes C., Hanyecz A., Mikecz K., Bremer E. G., Glant T. T. Gene expression profiling in murine autoimmune arthritis during the initiation and progression of joint inflammation. Arthritis Res Ther 2005; 7: R196–207
   Google Scholar